ArticleMedical oncology (Northwood, London, England)2022
Bioinformatics analysis of recurrent deletion regions in neuroblastoma.
Article in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- In vitro assessment of siRNA-mediated LRP5 silencing and temozolomide treatment in glioblastoma and brain cancer stem cells.Molecular genetics and genomics : MGG · 2026Article
- Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.Journal of personalized medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma (NB) is the most common extra-cranial solid tumor in childhood. Very few genes in recurrent deletion regions have been identified as tumor suppressors for NB, and interactions among proteins encoded by genes in these regions have been overlooked. This study aims to identify possible tumor suppressor genes located within regions commonly deleted in NB tumors and to show possible interaction network of proteins encoded by genes in these regions by bioinformatics analysis. The genes localized in the recurrent deletion regions were identified using the Ensembl BioMart web-tool. GSE1824 microarray dataset was analyzed to determine downregulated differently expressed genes (dDEGs) selected from deletion regions using Orange Canvas software. The DAVID v6.8 tool and Reactome database were used to perform gene ontology and pathway enrichment analysis, respectively. The protein-protein interaction (PPI) network and sub-module analysis were conducted by STRING database and Cytoscape plugin MCODE software, respectively. Copy number variation status and mutations of hub genes were examined in TARGET neuroblastoma dataset using UCSC Xena platform. Biological processes of genes were specific to chromosomes. The 219 genes selected from these regions were found to be downregulated. A PPI network was constructed for dDEGs. Copy number losses and mutations were observed for hub genes. Hub genes identified in the current study may act as tumor suppressors in NB tumorigenesis. Disruption of protein-protein interaction network consisting of proteins encoded by genes on various recurrent deletion regions may give rise to NB by interrupting gene regulatory network orchestrating neural crest formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.